CYTK Cytokinetics Incorporated

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Second Annual Muscle Biology-Focused Research Symposium

Highlighting Recent Innovations in the Field

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA.

“CLIMB was born out of our vision to bring together key contributors in muscle biology across academia and industry to foster meaningful scientific exchange and showcase novel research,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As pioneers and leaders in muscle biology, we remain committed to advancing the field by deepening collective understandings underlying muscle-related diseases and disorders.”

CLIMB is an annual one-day research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of novel research in the field of muscle biology. Presentations will focus on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology. Expert speakers include:

  • Keynote Speaker: John C. Marioni, Ph.D., Senior Vice President, Head of Computational Sciences, Genentech Research and Early Development
  • Craig Blanchette, Ph.D., Senior Vice President, Head of Research, Switch Therapeutics
  • Helen Blau, Ph.D., Donald E. and Delia B. Baxter Foundation Professor; Director, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine
  • Sharlene M. Day, M.D., Presidential Professor and Director of Translational Research, Division of Cardiovascular Medicine and Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine
  • W. Michael Flanagan, Ph.D., Chief Scientific Officer, Avidity Biosciences
  • Douglas Millay, Ph.D., Professor of Pediatrics, Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati
  • Fabio Rossi, M.D., Ph.D., Professor, School of Biomedical Engineering and Department of Medical Genetics, Scientific Director, BC Regenerative Medicine Initiative, University of British Columbia
  • Robin M. Shaw, M.D., Ph.D., Director, Nora Eccles Harrison Cardiovascular Research and Training Institute, Professor of Medicine, University of Utah
  • Jil C. Tardiff, M.D., Ph.D., Professor of Biomedical Engineering, Medicine, and Cellular and Molecular Medicine, University of Arizona
  • Paul Titchenell, Ph.D., Executive Director, Metabolic Physiology, Eli Lilly and Company

    Presenting research completed at the University of Pennsylvania Perelman School of Medicine

To attend CLIMB in person, register online by May 23, 2025, at .

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit and follow us on , , and .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates and our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:

Cytokinetics

Diane Weiser

Senior Vice President, Corporate Affairs

(415) 290-7757



EN
15/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytokinetics Incorporated

 PRESS RELEASE

Cytokinetics to Participate in the Jefferies Global Healthcare Confere...

Cytokinetics to Participate in the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at . The webcas...

 PRESS RELEASE

Cytokinetics Presents Additional Data Related to Aficamten at the Euro...

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress  Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy...

 PRESS RELEASE

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first ann...

 PRESS RELEASE

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Bi...

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA. “CLIMB was born out of our vision t...

 PRESS RELEASE

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics Announces Positive Topline Results From MAPLE-HCM Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch